Laboratory Corporation Of America ( (LH) ) has released its Q4 earnings. Here is a breakdown of the information Laboratory Corporation Of America presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Laboratory Corporation Of America (Labcorp) is a global leader in laboratory services, providing innovative diagnostics and drug development solutions to improve health outcomes worldwide. The company caters to healthcare professionals, pharmaceutical companies, and patients, operating in over 100 countries.
In its latest earnings report, Labcorp announced a strong financial performance for the fourth quarter and full year of 2024, demonstrating notable revenue and earnings growth. The company also outlined its strategic guidance for 2025, aiming to sustain its growth momentum.
Key financial highlights include a quarterly revenue increase to $3.33 billion, up from $3.03 billion in the previous year, and a full-year revenue of $13.01 billion, compared to $12.16 billion in 2023. The diluted EPS for Q4 rose to $1.70 from a loss of $1.95, while the adjusted EPS reached $3.45 from $3.30. Free cash flow also surged to $665.1 million in Q4, reflecting a robust cash position.
Labcorp’s strategic initiatives included completing significant acquisitions and launching new tests in key specialty areas, such as oncology and neurology. The company aims to expand its laboratory services partnerships and introduce new diagnostic solutions, further solidifying its market position.
Looking ahead, Labcorp projects a revenue range of $13.88 billion to $14.05 billion for 2025, with adjusted EPS anticipated between $15.60 and $16.40. The company remains focused on driving organic growth and enhancing its diagnostic and biopharma services offerings, positioning itself for continued success in the coming year.
